Ireland
--:--IST
Clinical Trials in the EU / 2025-523896-44-00
Authorised, recruiting Phase III

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial

2025-523896-44-00 · tracked via the Priya Life Science EU tracker
Sponsor
GWT-Tud GmbH
Sponsor type
Pharmaceutical company
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
08/06/2026
Enrollment target
60
Sites
Austria, Germany

Condition studied

Congenital hemophilia A (HA), Synovitis

Investigational medicinal product(s)

ALTUVOCT 2 000 IU powder and solvent for solution for injectionALTUVOCT 250 IU powder and solvent for solution for injectionALTUVOCT 3 000 IU powder and solvent for solution for injectionALTUVOCT 500 IU powder and solvent for solution for injectionALTUVOCT 1 000 IU powder and solvent for solution for injection

Every trial of Efanesoctocog alfa across our registers →

Eligibility

Age group
65+ years, 18-64 years
Sex
Male

Primary endpoint

Proportion of patients with treatment response (TR) after 12 months. TR is defined as a reduction or resolution of synovial hypertrophy in at least one affected joint according to the synovial hypertrophy domain of the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score performed by blinded ultrasound expert (BLUE) team

Endpoint detail

related to pharmacokinetics and efficacy for bleed prevention of ERT: ■ FVIII trough level ■ Time spent at FVIII activity >30 IU/dL ■ Time spent at FVIII activity >50 IU/dL ■ Annualized bleeding rate (ABR, all treated bleeds) and annualized joint bleeding rate (AjBR, treated joint bleeds only), related to assessments and clinical relevance of synovitis: ■ Proportion of joints with TR ■ Proportion of patients with complete resolution of synovitis in all of their joints, related to safety of efanesoctocog alfa: ■ Treatment-emergent adverse events (TEAE)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523896-44-00 on CTIS ↗ ← All trials in the EU